-
公开(公告)号：US20240325340A1
公开(公告)日：2024-10-03
申请号：US18292464
申请日：2022-07-27
IPC分类号： A61K31/352 , A61K31/165 , A61K31/433 , C07D311/04
CPC分类号： A61K31/352 , A61K31/165 , A61K31/433 , C07D311/04
摘要： The invention relates in one aspect to compounds, pharmaceutical compositions thereof, and methods using the same for selectively activating either all or a single isoform of Akt. Isoform selective-targeting is necessary for avoiding pathologies driven by concomitantly activated Akt1, Akt2 and/or Akt3.
-
公开(公告)号：US20240043396A1
公开(公告)日：2024-02-08
申请号：US18265472
申请日：2022-01-27
IPC分类号： C07D311/04 , C07D405/04 , C07D407/04 , C07D221/08 , C07D491/052 , C07D401/10 , C07D405/10 , C07D491/16 , C07D471/04
CPC分类号： C07D311/04 , C07D405/04 , C07D407/04 , C07D221/08 , C07D491/052 , C07D401/10 , C07D405/10 , C07D491/16 , C07D471/04
摘要： The present application provides compounds and methods for treating ocular fibrotic pathologies, including using D1 and/or D5 receptor agonists for treating proliferative vitreoretinopathy.
-
公开(公告)号：US11812774B2
公开(公告)日：2023-11-14
申请号：US16311851
申请日：2017-06-23
发明人： Suguru Nakajima , Yumi Sasanuma , Yoshihide Matsuo
IPC分类号： A23L3/3544 , A23L3/3481 , A23L5/20 , A23L29/00 , A23F3/16 , A61K8/49 , A61K8/60 , A61K47/22 , C07D311/04 , C09K3/00
CPC分类号： A23L3/3544 , A23F3/16 , A23L3/3481 , A23L5/27 , A23L29/00 , A23V2002/00 , A23V2200/048 , A61K8/49 , A61K8/60 , A61K47/22 , C07D311/04 , C09K3/00
摘要： The present invention relates to a browning-inhibiting composition containing a compound represented by the following formula (1):
wherein R21, R22, R23, R24, R26 and R27 each independently represent a hydrogen atom or a substituent, and at least one of R21 or R23 is a hydrogen atom; when R23 represents a hydrogen atom, at least one of R22 or R24 represents a substituent; R25 represents a hydrogen atom, an oxygen atom, or a substituent; R22 and R23, or R23 and R24 may be bonded together to form a ring with an oxygen atom and a carbon atom to which these Rs are bonded; R25 and R26, or R26 and R27 may be bonded together to form a ring structure with carbon atoms to which these Rs are bonded; X represents an oxygen atom or —CH2—; and a dashed line may represent a double bond.-
公开(公告)号：US09962690B2
公开(公告)日：2018-05-08
申请号：US15307077
申请日：2015-04-21
CPC分类号： B01J31/2409 , B01J31/2404 , B01J2231/32 , B01J2231/324 , B01J2531/18 , B01J2531/822 , B01J2531/828 , C07C2/66 , C07C67/30 , C07C2531/24 , C07D311/04 , C07F9/58 , C07F15/0073 , C07F15/0093
摘要： The present invention deals with the synthesis and applications of new cationic compounds being useful as metal ligands. Specifically, N-alkyl/aryl substituted pyridiniophosphines are prepared and used as ligands for transition metals. The so-obtained metal complexes and their use as catalysts in chemical synthesis is also described. It also worth mentioning that N-alkyl/aryl pyridiniophosphines can be synthesized through a short, scalable and highly modular route.
-
公开(公告)号：US20170313673A1
公开(公告)日：2017-11-02
申请号：US15524011
申请日：2015-04-17
申请人： Osman Nidai ÖZES
发明人： Osman Nidai ÖZES
IPC分类号： C07D311/04 , C07C43/20 , C07C43/23 , C07C49/84
CPC分类号： C07D311/04 , C07C43/202 , C07C43/23 , C07C49/84 , C07C409/02
摘要： Disclosed are chromene-2 derivatives and the use thereof in the treatment of fibrosis. Specifically, disclosed are the derivatives of a compound having a main structure of 6,7-dimethoxy-chromenylium perchlorate (1) and pharmaceutical compositions, combinations and pharmaceutically suitable salts thereof for the treatment of fibrosis.
-
公开(公告)号：US20170073321A1
公开(公告)日：2017-03-16
申请号：US15310641
申请日：2015-05-13
发明人： Yasuteru URANO , Mako KAMIYA , Tomohiro DOURA
IPC分类号： C07D311/04 , C12Q1/40
CPC分类号： C07D311/04 , C07H17/04 , C12Q1/40 , G01N2333/938
摘要： Provided is an enzyme-specific fluorescent compound capable of being retained in cells, which can emit fluorescence specifically in a target cell, particularly a cell capable of expressing a reporter enzyme such as β-galactosidase, and can covalently bind to a protein in the cell to exhibit an excellent property of being retained in the cell. The fluorescent compound comprises a compound represented by formula (I′) or a salt thereof. In formula (I′), A, X, Y and R1 to R9 are as described in claim 1.
摘要翻译： 提供能够保留在细胞中的酶特异性荧光化合物，其可以在靶细胞，特别是能够表达报告酶如β-半乳糖苷酶的细胞中特异性发射荧光，并且可以共价结合细胞中的蛋白质 以表现出保留在细胞中的优异性质。 荧光化合物包含由式（I'）表示的化合物或其盐。 在式（I'）中，A，X，Y和R 1至R 9如权利要求1所述。
-
公开(公告)号：US20170008869A1
公开(公告)日：2017-01-12
申请号：US15197929
申请日：2016-06-30
申请人： NORAMCO, INC.
发明人： Lukas Dialer , Denis Petrovic , Ulrich Weigl
IPC分类号： C07D311/80 , C07C37/11 , C07D205/04 , C07C37/62
CPC分类号： C07D311/78 , C07C37/11 , C07C37/14 , C07D205/04 , C07D311/04 , C07D311/80
摘要： The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
-
公开(公告)号：US20160318882A1
公开(公告)日：2016-11-03
申请号：US15208329
申请日：2016-07-12
发明人： Agostino MARASCO , Giuseppe ALVARO , Anne DÈCOR , Dieter HAMPRECHT , Paolo DAMBRUOSO , Simona TOMMASI
IPC分类号： C07D249/12 , C07D401/04 , C07D405/14 , C07C255/48 , C07C43/225
CPC分类号： C07D249/12 , C07C43/225 , C07C43/29 , C07C43/313 , C07C255/37 , C07C255/46 , C07C255/48 , C07C2601/02 , C07D307/87 , C07D307/94 , C07D311/04 , C07D311/76 , C07D311/96 , C07D401/04 , C07D405/14
摘要： Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.
-
9.发明申请公开(公告)号：US20160229831A1
公开(公告)日：2016-08-11
申请号：US14849859
申请日：2015-09-10
申请人： Acucela Inc.
发明人： Vladimir A. Kuksa , Mark W. Orme , Feng Hong , Ryo Kubota
IPC分类号： C07D335/02 , C07D213/38 , C07D211/26 , C07D307/81 , C07D307/14 , C07D211/60 , C07D233/96 , C07D311/04 , C07D207/09 , C07D211/76 , C07D333/12 , C07D207/26 , C07D279/02 , C07D211/96 , C07D209/08 , C07D233/64 , C07D309/06
CPC分类号： C07D335/02 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/382 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/445 , A61K31/4465 , A61K31/505 , C07D207/08 , C07D207/09 , C07D207/26 , C07D209/08 , C07D209/14 , C07D211/22 , C07D211/26 , C07D211/60 , C07D211/76 , C07D211/96 , C07D213/30 , C07D213/38 , C07D233/64 , C07D233/96 , C07D239/26 , C07D279/02 , C07D307/12 , C07D307/14 , C07D307/80 , C07D307/81 , C07D309/04 , C07D309/06 , C07D311/04 , C07D311/58 , C07D333/12 , C07D333/16 , C07D333/20
摘要： The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
-
10.发明授权公开(公告)号：US09290472B2
公开(公告)日：2016-03-22
申请号：US14116023
申请日：2012-05-07
IPC分类号： C07D311/94 , C07D453/02 , C07D405/12 , C07D491/048 , C07D493/04
CPC分类号： C07D311/94 , C07D311/04 , C07D405/12 , C07D453/02 , C07D491/048 , C07D493/04
摘要： The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
摘要翻译： 本发明提供三环化合物及其在治疗医学疾病如肥胖症中的用途。 提供制备各种三环化合物的药物组合物和方法。 化合物被认为具有抗甲硫氨酰氨基肽酶2的活性。
-
-
-
-
-
-
-
-
-
搜索结果
237 条记录 (耗时 0.04 秒)
